Drug Profile
Meningococcal vaccine group B conjugate - Sanofi-Aventis
Alternative Names: Group B meningococcal polysaccharide conjugate vaccine - sanofiLatest Information Update: 06 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Meningococcal group B infections
Most Recent Events
- 15 Apr 2008 Discontinued - Phase-I for Meningococcal group B infections in France (IM)
- 26 May 2006 This vaccine is still in active development
- 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur